earnings
confidence high
sentiment positive
materiality 0.75
Indivior Q3 net revenue $314M (+2% YoY); raises FY2025 guidance materially
Indivior Pharmaceuticals, Inc.
2025-Q3 EPS reported
$0.85
revenue$881,000,000
- SUBLOCADE net revenue $219M (+15% YoY); U.S. SUBLOCADE up 14% to $203M.
- Adjusted EBITDA $120M (+14% YoY); non-GAAP diluted EPS $0.72 vs $0.49 YoY.
- FY2025 net revenue guidance raised to $1.18-1.22B; adjusted EBITDA now $400-420M.
- Plans to exit several ROW markets, discontinue OPVEE sales support, saving at least $150M annually from 2026.
- Cash and investments $473M at Q3 end, up $125M from year-end 2024.